Savant Capital LLC Has $833,000 Position in Kenvue Inc. $KVUE

Savant Capital LLC increased its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 186.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 48,311 shares of the company’s stock after acquiring an additional 31,421 shares during the period. Savant Capital LLC’s holdings in Kenvue were worth $833,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Kenvue by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 234,951,484 shares of the company’s stock valued at $4,052,913,000 after acquiring an additional 1,604,040 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Kenvue by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 49,862,574 shares of the company’s stock valued at $856,778,000 after acquiring an additional 371,322 shares in the last quarter. American Century Companies Inc. boosted its position in Kenvue by 22.4% in the third quarter. American Century Companies Inc. now owns 37,046,660 shares of the company’s stock valued at $601,267,000 after buying an additional 6,781,640 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Kenvue by 13.5% in the third quarter. Dimensional Fund Advisors LP now owns 23,127,234 shares of the company’s stock valued at $375,377,000 after buying an additional 2,747,952 shares in the last quarter. Finally, Van ECK Associates Corp boosted its position in Kenvue by 101.3% in the third quarter. Van ECK Associates Corp now owns 18,361,581 shares of the company’s stock valued at $298,008,000 after buying an additional 9,240,434 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of KVUE stock opened at $17.32 on Wednesday. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $23.63. The firm’s 50 day moving average is $17.40 and its 200-day moving average is $17.47. The firm has a market capitalization of $33.25 billion, a price-to-earnings ratio of 20.38, a PEG ratio of 1.32 and a beta of 0.54. The company has a current ratio of 0.98, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The company had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. During the same period in the prior year, the business earned $0.24 earnings per share. Kenvue’s quarterly revenue was up 4.5% on a year-over-year basis. Sell-side analysts forecast that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were given a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.8%. The ex-dividend date was Wednesday, May 13th. Kenvue’s dividend payout ratio is presently 97.65%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on KVUE. Canaccord Genuity Group boosted their price target on shares of Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research report on Wednesday, February 18th. Barclays reduced their price target on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 14th. UBS Group reduced their price target on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 7th. Weiss Ratings lowered shares of Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday. Finally, Argus upgraded shares of Kenvue to a “hold” rating in a research report on Friday, March 6th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have given a Hold rating to the company. Based on data from MarketBeat.com, Kenvue has a consensus rating of “Hold” and a consensus price target of $19.33.

Insider Activity

In other news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.59% of the company’s stock.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.